Travere Therapeutics, Inc. (TVTX) Fair Value 2026

TVTX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.5 /10

32 fundamental signals · 5 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-08-28, Travere Therapeutics, Inc. (TVTX) trades at $65.67, versus a $6.46 median fair value across its 5 active models — 90.2% below the current price. QOC: 6.5/10. Value Trap Risk: 26/100 (LOW). 5/13 models active. Within that set, the Bayesian DCF component alone returns $5.95.

Key Facts

Ticker
TVTX
Price
$65.67
Quality Score
6.5/10
Value Trap Risk
26/100
Models Active
5/13
Last Updated
Strength: 5 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Travere Therapeutics, Inc. (TVTX) Undervalued or Overvalued in 2026?

According to CirclFi’s 5-model valuation engine, Travere Therapeutics, Inc. (TVTX) appears overvalued as of : the median of 5 independent fair value estimates is $6.46, 90.2% below the current price of $65.67. Estimates range from $4.17 to $33.79. TVTX scores 6.5/10 on fundamental quality and 26/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. TVTX’s -90.2% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Travere Therapeutics, Inc. Stock in 2026? →

What Fair Value Does Each Model Give TVTX?

5 Intrinsic Value Models vs. Current Price ($65.67)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $5.95 -90.9%
Ensemble · Low Conviction
 $9.46 -85.6%
Unlock the Full Matrix

Access 3 additional models including Regime Cross-Sectional, FTNN Topology, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 5 Models →

Cancel anytime · No contracts · Instant access

What Is TVTX's Fair Value Range?

Spread across 5 independent models · $4.17 to $33.79

CirclFi's 5 active models place Travere Therapeutics, Inc. (TVTX) between $4.17 and $33.79 per share, a spread of 459% of the median. The median of that range — $6.46 — is the fair value CirclFi publishes for TVTX, against a current price of $65.67.

Low · FTNNHigh · Regime Cross
$4.17median $6.46$33.79
Where the range comes from
Most bearish modelFTNN Topology$4.17
Most bullish modelRegime Cross-Sectional$33.79
Model agreement0 bullish · 5 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for TVTX. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on TVTX, not a CirclFi price target. How each model works →

What Is Travere Therapeutics, Inc. (TVTX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Travere Therapeutics, Inc.'s intrinsic value is estimated at $6.46. Trading at its current price of $65.67, the valuation engine raises significant caution: 5 of 5 models flag downside risk, projecting a median implied return of -90.2%. The most optimistic model, Regime Cross, places fair value at $33.79 (-48.5%), while FTNN — the most conservative — estimates $4.17 (-93.6%). This +45.1% gap reflects genuine analytical uncertainty about Travere Therapeutics, Inc.'s intrinsic worth.

What Do the Models Say About TVTX?

5 of 13 models are currently active for TVTX. All 5 active models suggest the stock trades above fair value. Taken together, their median fair value for TVTX is $6.46 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $5.95 on its own, implying -90.9% downside from the current price. See which stocks rank higher →

How Does TVTX Rank in Biotechnology?

Among 625 Biotechnology stocks, TVTX ranks #82 by Quality of Company score. CirclFi's QOC score of 6.5/10 evaluates 32 fundamental signals. A score of 6.5 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to biotech businesses. For Travere Therapeutics, Inc., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.

Is TVTX a Value Trap?

CirclFi's Value Trap algorithm assigns TVTX a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

5 of 13 models are active for Travere Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Travere Therapeutics, Inc. scores 6.5 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +45.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every TVTX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across TVTX's 5 active models, average confidence is 35%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Travere Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ZEOXZeo ScientifiX, Inc.QOC 6.6VIRVir Biotechnology, Inc.QOC 6.5AXSMAxsome Therapeutics, Inc.QOC 6.6ZVRAZevra Therapeutics, Inc.QOC 6.5ACRSAclaris Therapeutics, Inc.QOC 6.6ASNDAscendis Pharma A/SQOC 6.5SLXNSilexion Therapeutics CorpQOC 5.4LRMRLarimar Therapeutics, Inc.QOC 4.7BCLIBrainstorm Cell Therapeutics Inc.QOC 3.8EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: ZEOX · VIR · AXSM · ZVRA · ACRS · ASND · SLXN · LRMR · BCLI · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to TVTX?

6 companies across all industries closest to TVTX’s Quality of Company score of 6.5/10.

PESIPerma-Fix Environmental Services, Inc.QOC 6.6SYSo-Young International Inc.QOC 6.5CLWClearwater Paper CorporationQOC 6.6SDRLSeadrill LimitedQOC 6.5HTZHertz Global Holdings, Inc.QOC 6.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: PESI · SY · CLW · SDRL · HTZ · NVDA

Where Does TVTX Sit in CirclFi's Biotechnology Rankings?

TVTX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Travere Therapeutics, Inc.’s Valuation?

What is Travere Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi puts Travere Therapeutics, Inc. (TVTX)'s intrinsic value at $6.46 — the median of 5 independent model estimates as of 2026-08-28, ranging from $4.17 to $33.79. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $5.95 on its own. The Quality of Company score is 6.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is TVTX overvalued or undervalued right now?

At $65.67, 0 of 5 active models suggest TVTX may be undervalued, while 5 indicate potential overvaluation. The median of all 5 fair value estimates is $6.46, 90.2% below the current price of $65.67 — a consensus view that TVTX is overvalued. The assessment depends on which methodology best fits Travere Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.5 mean for TVTX?

Travere Therapeutics, Inc.'s QOC of 6.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on TVTX?

CirclFi analyzes TVTX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 5 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on TVTX?

Of the 5 models currently active on TVTX, Regime Cross-Sectional is the most bullish at $33.79 per share, and FTNN Topology is the most bearish at $4.17. CirclFi's published fair value for TVTX is the median of that range, $6.46, not either extreme. The gap between the two ends equals 459% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is TVTX a value trap in 2026?

Travere Therapeutics, Inc.'s Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 5-model valuation engine, Travere Therapeutics, Inc. (TVTX) has a median fair value of $6.46 — 90.2% below the current price of $65.67 — as of 2026-08-28.” Source: circlfi.com/stock/TVTX/ · Methodology
Primary sources for this TVTX valuation
  • Financial statements: Travere Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001438533) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for TVTX as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 5 mathematical frameworks give you clarity on TVTX.

Unlock All 5 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

3 models hidden for TVTX Unlock All 5 — $39/mo